














This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Adams LA, Anstee QM.  
A fatty liver leads to a broken heart? 




© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
DOI link to article: 
http://dx.doi.org/10.1016/j.jhep.2016.03.012  
Date deposited:   
27/10/2016 
Embargo release date: 
26 March 2017  
Accepted Manuscript
A Fatty liver leads to a broken heart?




To appear in: Journal of Hepatology
Received Date: 17 March 2016
Accepted Date: 20 March 2016
Please cite this article as: Adams, L.A., Anstee, Q.M., A Fatty liver leads to a broken heart?, Journal of
Hepatology (2016), doi: http://dx.doi.org/10.1016/j.jhep.2016.03.012
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
Journal of Hepatology editorial 
 
 





 & Quentin M. Anstee 
2 
 
1. School of Medicine and Pharmacology, The University of Western Australia, Nedlands, 
Australia. 
2. Liver Research Group, Institute of Cellular Medicine, The Medical School, Newcastle University, 




Leon A. Adams MBBS, PhD, FRACP 
M503 
School of Medicine and Pharmacology, UWA 
QEII Medical Campus 
Verdun St 
Nedlands, WA 6009 
Australia 
 
T: +61 8 6151 1052  
F: +61 8 6151 1028 
Email: leon.adams@uwa.edu.au 
 
Dr Quentin M. Anstee BSc, MB BS, PhD, MRCP(UK) 
Senior Lecturer & Honorary Consultant Hepatologist, 
Institute of Cellular Medicine, 




 Floor, William Leech Building, 
Framlington Place, 
Newcastle-upon-Tyne, NE2 4HH, Great Britain. 
Telephone: + 44 (0) 191 208 7012  
Fax: + 44 (0) 191 208 0723 
Email:  quentin.anstee@ncl.ac.uk 
 
Word Count: 1023  Figures: 0   Tables: 0 
Abbreviations: NAFLD, non-alcoholic fatty liver disease; CVD, cardiovascular disease; cIMT, carotid 
intimal media thickness; FLI, Fatty Liver Index; GGT, gamma glutamyl transferase 
Keywords: NAFLD, cardiovascular disease, carotid intimal media thickness  
Conflict of Interest: Nil 
Financial Support: Nil 
Authors Contributions: LAA and QMA both contributed equally to the data review and interpretation 
for this editorial, the manuscript writing and editing. 
 
  
Non-alcoholic fatty liver disease (NAFLD) typically exists in a milieu of disturbed metabolism, including 
increased total body adiposity, insulin resistance, impaired glucose tolerance and dyslipidemia[1].  
Cumulatively, these factors increase the risk for cardiovascular disease (CVD), and so it is not surprising 
that CVD is the leading cause of death in NAFLD patients.[2] The challenge over the past decade has 
been to tease apart the complex and inter-dependent relationships between NAFLD and these 
etiological factors, to establish whether NAFLD per se increases the risk of developing CVD. The 
validation of NAFLD as a significant additional risk factor would have direct relevance for primary 
preventative strategies against cardiovascular disease. 
 
In this edition of the journal, Pais and colleagues present both new cross-sectional and longitudinal 
evidence that NAFLD is an important and independent risk factor for the development of 
atherosclerosis and therefore CVD.[3] In a cross-sectional analysis of 5671 individuals attending a 
cardiovascular disease primary prevention clinic, the presence of fatty liver was associated with greater 
cardiovascular risk, independent of traditional risk factors including age, sex, smoking, hypertension, 
diabetes and C-Reactive Protein. Cardiovascular risk was determined by carotid intimal media thickness 
(cIMT), which is a validated predictor of myocardial infarction and stroke.[4] Furthermore, repeat 
assessment in 1,872 individuals after a mean follow-up of eight years, demonstrated that incident fatty 
liver was associated with a greater increase in cIMT and baseline fatty liver predicted the development 
of carotid plaques after adjustment for a range of cardiovascular risk factors. 
 
Although this data strongly suggests NAFLD confers an increased risk over and above its association 
with traditional cardiac risk factors, a few caveats are worth noting. The diagnosis of NAFLD was based 
on the Fatty Liver Index (FLI), a calculated score that combines body mass index, waist circumference, 
serum triglycerides and gamma-glutamyl transferase (GGT) to provide a composite value ranging from 
0-100.[5] Whilst the use of non-invasive tests like FLI is a frequent and necessary compromise in large-
scale retrospective studies of this type, validation of the FLI against magnetic resonance spectroscopy 
which is the gold standard for hepatic fat quantification, has demonstrated a score >60 is specific but 
only modestly sensitive for a diagnosis of NAFLD.[6]  Moreover, of the FLI components, waist 
circumference was the dominant driver of the association between the FLI and cIMT and so is a 
potential confounding variable. Nevertheless, these results are supported by other cross-sectional 
population-based studies and meta-analysis that have demonstrated NAFLD to be independently 
associated with predictors of cardiovascular disease reflecting structural and functional vascular 
abnormalities including endothelial dysfunction, arterial stiffness and myocardial dysfunction.[7-10]  
 
  
It should not be surprising that NAFLD plays a likely role in the genesis of CVD. The normal glucose and 
lipid homeostasis within the liver becomes disturbed with the accumulation of hepatic fat, resulting in 
hepatic insulin resistance, increased fasting glucose levels and an atherogenic lipid profile.[1] Moreover, 
weight gain in NAFLD subjects, exacerbates the adverse cardiovascular risk profile when compared with 
non-NAFLD subjects who have equivalent body fat mass and weight gain.[11] The fatty liver is also a 
producer of a number of inflammatory pro-atherogenic cytokines, hyper-coagulable factors and 
adhesion molecules, which have been implicated in the pathogenesis of myocardial dysfunction and 
atherosclerosis[12]. 
 
On this background of evidence demonstrating biological plausibility and cross-sectional association 
between NAFLD and CVD, the longitudinal findings of Pais et al, add a further critical piece of 
information by confirming that subjects with fatty liver were more likely to develop carotid plaque over 
time. A number of other studies also support the notion that NAFLD is predictive of incident 
cardiovascular disease and cardiovascular mortality.[13-17] However, some of these cohort studies 
have suggested that that the increase in CVD risk may be limited to sub-groups of NAFLD patients, such 
as those with advanced fibrosis[13], type 2 diabetes[15] or men with an elevated GGT[8].  Thus, there 
are likely to be other factors that modify the association between NAFLD and CVD. One such modifying 
factor may be genetic variation. An example is the TM6SF2 gene, where minor allele carriage has been 
identified as a risk factor for NAFLD and hepatic fibrosis[18], but is also associated with a reduced risk of 
cardiovascular events.[19-21] Animal studies suggest TM6SF2 may be involved in lipid efflux from the 
liver: overexpression spares the liver from triglyceride accumulation but leads to higher circulating lipid 
levels, whereas deletion induces NAFLD but lowers peripheral lipid levels.[22] 
 
Taken as a whole, the bulk of evidence suggests NAFLD increases CVD risk, although this relationship 
may be modified by other factors. The clinical implications of this paradigm may alter the decision to 
institute primary prevention strategies with anti-platelet, lipid lowering or anti-hypertensive drugs. 
Current recommendations for CVD prevention in the general population involve the calculation of 
future cardiovascular risk using algorithms such as the Framingham risk calculator or the SCORE risk 
assessment system that are based on traditional risk factors including age, blood pressure, cholesterol 
and smoking, but not NAFLD. Decisions to institute primary preventative pharmaco-therapy are then 
based on a calculated future risk of CVD, often defined as a 10-year absolute risk of ≥ 20%.[23] 
Although the Framingham risk score has been validated as a useful tool in NAFLD patients[24], it is not 
yet established whether the addition of NAFLD as a predictive factor in this or other CVD risk 
calculators, would increase their accuracy for determining future cardiovascular events.  
 
  
A further intriguing thought is whether fatty liver can be a therapeutic target for cardiovascular risk 
reduction? Although causality can not be established, the PIVENS randomized controlled trial examining 
pioglitazone, vitamin E or placebo demonstrated that NASH resolution was associated with an 
improvement in atherogenic lipid profiles regardless of treatment group, as well as improved 
Framingham risk score.[25] 
 
To summarize, the study by Pais et al provides further support for the view that NAFLD is an 
independent risk factor for atherosclerosis and therefore CVD. Clinicians should be aware of the 
increased cardiovascular risk in patients with NAFLD and consequently screen for conventional 
cardiovascular risk factors and use accepted risk calculators to make decisions regarding preventative 
pharmacotherapy, including statins. Additional prospective studies will be needed to determine what 
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